Ally Bridge Group NY LLC Cuts Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Ally Bridge Group NY LLC lessened its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) by 69.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 122,424 shares of the company's stock after selling 277,042 shares during the period. Jasper Therapeutics comprises about 2.2% of Ally Bridge Group NY LLC's portfolio, making the stock its 19th largest holding. Ally Bridge Group NY LLC owned 0.82% of Jasper Therapeutics worth $2,617,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Boxer Capital Management LLC bought a new position in Jasper Therapeutics during the fourth quarter worth $7,483,000. T. Rowe Price Investment Management Inc. acquired a new position in Jasper Therapeutics in the 4th quarter valued at $1,757,000. Schroder Investment Management Group bought a new position in Jasper Therapeutics during the fourth quarter worth about $1,237,000. Russell Investments Group Ltd. raised its stake in Jasper Therapeutics by 16.9% in the 4th quarter. Russell Investments Group Ltd. now owns 247,272 shares of the company's stock worth $5,287,000 after purchasing an additional 35,746 shares in the last quarter. Finally, Propel Bio Management LLC bought a new stake in Jasper Therapeutics in the 4th quarter valued at about $428,000. 79.85% of the stock is currently owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Down 3.3 %

Shares of NASDAQ:JSPR traded down $0.18 during midday trading on Monday, hitting $5.23. 114,228 shares of the stock traded hands, compared to its average volume of 287,704. The stock has a market capitalization of $78.57 million, a PE ratio of -1.10 and a beta of 2.55. Jasper Therapeutics, Inc. has a one year low of $3.13 and a one year high of $26.84. The business's 50 day moving average is $4.75 and its two-hundred day moving average is $11.87.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). As a group, sell-side analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

JSPR has been the subject of a number of recent analyst reports. Royal Bank of Canada cut their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. JMP Securities reissued a "market outperform" rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a research note on Monday, January 6th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, UBS Group assumed coverage on Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Jasper Therapeutics currently has an average rating of "Buy" and an average target price of $62.50.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.